Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on January 14, 2019, 10:36:22 am
-
In a recent trial, Galmed Pharmaceuticals’ Aramchol showed promise in reducing liver fat among those with non-alcoholic steatohepatitis (NASH), also known as fatty liver disease, Healio reports.
Presenting their findings at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco (The Liver Meeting), researchers conducted a Phase IIb trial of Aramchol treatment among 247 people who had NASH according to a biopsy. These individuals were also overweight or obese and had prediabetes or diabetes.
For more...
https://www.hepmag.com/article/aramchol-lowers-liver-fat-fatty-liver-disease